References
- Global Initiative for Chronic Obstructive Lung Disease (GOLD)Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease Updated 2009. Available from: http://www.goldcopd.org. Accessed 2010 Sep 16.
- WoutersEFCreutzbergECScholsAMSystemic effects in COPDChest2002121Suppl 5S127130
- DecramerMRennardSTroostersTCOPD as a lung disease with systemic consequences – clinical impact, mechanisms, and potential for early interventionCOPD2008523525618671149
- CasaburiRMahlerDAJonesPWA long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary diseaseEur Respir J20021921722411866001
- VinckenWvan NoordJAGreefhorstAPMImproved health outcomes in patients with COPD during 1 yr’s treatment with tiotropiumEur Respir J20021920921611871363
- DonohueJFvan NoordJABatemanEDA 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterolChest2002122475512114338
- BrusascoVHodderRMiravitllesMKorduckiLTowseLKestenSHealth outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPDThorax20035839940412728159
- TashkinDPCelliBSennSA 4-year trial of tiotropium in chronic obstructive pulmonary diseaseN Engl J Med20083591543155418836213
- JonesPWQuirkFHBaveystockCMLittlejohnsPA self-complete measure of health status for chronic airflow limitationAm Rev Respir Dis1992145132113271595997
- BrazierJEHarperRJonesNMBValidating the SF-36 health survey questionnaire: New outcome measure for primary careBMJ19923051601641285753
- WareJEJrSherbourneCDThe MOS 36-item Short-form Health Survey (SF-36). 1: Conceptual framework and item selectionMed Care1992304734831593914
- WareJEJrGandekBOverview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) ProjectJ Clin Epidemiol1998519039129817107
- GummessonCAtroshiAEkdahlCPerformance of health-status scales when used selectively or within multi-scale questionnaireBMC Med Res Methodol20033312585967
- GlaabTVogelmeierCBuhlROutcome measures in chronic obstructive pulmonary disease (COPD): Strengths and limitationsRespir Res2010117920565728
- MichelMGoepelMTreatment satisfaction of patients with lower urinary tract symptoms: Randomised controlled trials vs real life practiceEur Urol200038Suppl 1404711111207
- VoshaarTLapidusRMaleki-YazdiRA randomized study of tiotropium Respimat® Soft Mist inhaler vs ipratropium pMDI in COPDRespir Med2008102324117996436
- CohenJStatistical Power Analysis for the Behavioral Sciences1st revised edHillsdale, NJLawrence Erlbaum Associates Inc1977
- GlaabTRau-BergerHWolfKFreytagFTiotropium improves quality of life and physical function in COPDAm J Respir Crit Care Med2008177 Abstr 646.
- GlaabTRau-BergerHImprovement in physical functioning in COPD patients with tiotropiumAm J Respir Crit Care Med2009179 Abstr 4559.
- KestenSJaraMWentworthCLanesSPooled clinical trial analysis of tiotropium safetyChest20061301695170317166984
- KestenSCelliBDecramerMLeimerITashkinDTiotropium HandiHaler® in the treatment of COPD: A safety reviewInt J Chron Obstruct Pulmon Dis2009439740920037679
- van NoordJACornelissenPJGAumannJ-LPlatzJMuellerAFogartyCThe efficacy of tiotropium administered via Respimat® Soft Mist Inhaler or HandiHaler® in COPD patientsRespir Med2009103222919022642
- SchürmannWSchmidtmannSMoroniPMasseyDQidanMRespimat® Soft Mist™ inhaler versus hydrofluoroalkane metered dose inhaler: Patient preference and satisfactionTreat Respir Med20054536115725050
- HodderRReesePRSlatonTAsthma patients prefer Respimat® Soft Mist™ Inhaler to Turbuhaler®Int J Chron Obstruct Pulmon Dis2009422523219554196
- ConcatoJShahNHorwitzRRandomized, controlled trials, observational studies, and the hierarchy of research designsN Engl J Med20003421887189210861325